Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMINGO-01: GLSI-100 in HER2/Neu Positive Breast Cancer
NCT05232916Phase 3Recruiting
- Sponsor
- Greenwich LifeSciences, Inc.
- Start
- Dec 2022
- Primary completion
- Dec 2031
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
A Phase 3 trial of GP2 peptide in breast cancer, sponsored by Greenwich LifeSciences, Inc.. Started Dec 2022; status: recruiting.
02
Drugs
GP2 peptide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05232916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232916.